Edition:
United States

Immutep Ltd (IMMP.OQ)

IMMP.OQ on NASDAQ Stock Exchange Global Market

1.56USD
15 Dec 2017
Change (% chg)

$-0.10 (-6.02%)
Prev Close
$1.66
Open
$1.71
Day's High
$1.71
Day's Low
$1.49
Volume
16,007
Avg. Vol
14,648
52-wk High
$3.25
52-wk Low
$1.40

Summary

Name Age Since Current Position

Marc Voigt

42 2016 Chief Executive Officer, Executive Director

Deanne Miller

39 2016 Chief Operating Officer, General Counsel, Company Secretary

Frederic Triebel

61 2014 Chief Scientific Officer & Chief Medical Officer

Grant Chamberlain

2017 Non-Executive Director

Russell Howard

65 2013 Non-Executive Director

Pete Meyers

47 2014 Non-Executive Director

Matthew Gregorowski

2015 IR Contact Officer

Biographies

Name Description

Marc Voigt

Mr. Marc Voigt serves as Chief Executive Officer, Executive Director of Prima Biomed Ltd. Marc has more than 18 years of experience in the financial and biotech industry, having joined the Prima team in 2011 as the General Manager, European Operations based in Berlin, Germany. In May 2012, he became Prima’s Chief Business Officer and in November 2012 its Chief Financial Officer, as well as continuing to focus on its European operations. Having started his career at the Allianz Group working in pension insurances and funds, he moved to net. IPO AG, a publicly-listed boutique investment bank in Frankfurt where he was focused on IPOs and venture capital investments. Marc then worked for a number of years as an investment manager for a midsize venture capital fund based in Berlin, specializing in healthcare. He also gained considerable operational experience while serving in different management roles with Revotar Biopharmaceuticals, Caprotec Bioanalytics and Medical Enzymes AG respectfully, where he handled several successful licensing transactions and financing rounds.

Deanne Miller

Ms. Deanne Miller, LLB, serves as Chief Operating Officer, General Counsel, Company Secretary of Prima BioMed Ltd. Ms Miller has broad commercial experience having held legal, investment banking, regulatory compliance and tax advisory positions, including, Legal Counsel at RBC Investor Services, Associate Director at Westpac Group, Legal & Compliance Manager at Macquarie Group, Regulatory Compliance Analyst at the Australian Securities and Investment Commission, and Tax Advisor at KPMG. She joined Prima as General Counsel and Company Secretary in October 2012. She has a Combined Bachelor of Laws (Honours) and Bachelor of Commerce, Accounting and Finance (double major) from the University of Sydney. She is admitted as a solicitor in NSW and member of the Law Society of NSW.

Frederic Triebel

Dr. Frederic Triebel, M.D., Ph.D., serves as Chief Scientific Officer & Chief Medical Officer of the Company. He was the scientific founder of Immutep S.A. (2001) and served as the Scientific and Medical Director at Immutep from 2004. Before starting Immutep, he was Professor in Immunology at Paris University. While working at Institut Gustave Roussy (IGR), a large cancer centre in Paris, he discovered the LAG-3 gene in 1990 and continued working on this research program since then, identifying the functions and medical usefulness of this molecule. He headed a research group at IGR while also being involved in the biological follow-up of cancer patients treated in Phase I/II immunotherapy trials. He was Director of an INSERM Unit from 1991 to 1996. First trained as a clinical haematologist, Prof. Triebel holds a Ph.D. in immunology (Paris University) and successfully developed several research programs in immunogenetics and immunotherapy, leading to 144 publications and 16 patents.

Grant Chamberlain

Mr. Grant Chamberlain is Non-Executive Director of the Company. Mr Chamberlain is a corporate adviser and entrepreneur. He has over 20 years’ experience in investment banking and has advised on many of the largest mergers and acquisitions transactions in Australia during that time. Mr Chamberlain was Head of Mergers & Acquisitions and Financial Sponsors Australia at Bank of America Merrill Lynch until June 2017 and prior to joining Bank of America Merrill Lynch in 2013, Mr Chamberlain held senior positions at Nomura Australia and Deutsche Bank. He began his career as a corporate lawyer at Freehill Hollingdale & Page. Mr Chamberlain earned a Bachelor of Laws with Honours and a Bachelor of Commerce from the University of Melbourne.

Russell Howard

Dr. Russell John Howard, Ph.D., serves as Non-Executive Director of Prima Biomed Ltd. Dr. Russell is an Australian scientist, executive manager and entrepreneur. He was a pioneer in molecular parasitology and commercialization of “DNA Shuffling”. He is an inventor of 9 patents and has over 150 scientific publications. After his PhD in biochemistry from the University of Melbourne, he held positions at several research laboratories, including the National Institutes of Health in the USA where he gained tenure. In industry, Dr. Howard worked at Schering-Plough’s DNAX Research Institute in Palo Alto, CA; was the President and Scientific Director of Affymax, Inc. and co-founder and CEO of Maxygen, Inc. After its spin-out from GlaxoWellcome. As Maxygen’s CEO, Dr. Howard led its IPO on NASDAQ and a secondary offering, raising US$ 260 million. Maxygen developed and partnered dozens of technology applications and products. After leaving Maxygen in 2008, he started the Cleantech company Oakbio, Inc. And remains involved in several innovative companies in the USA and Australia. He is currently Executive Chairman of NeuClone Pty Ltd and Head of Commercial Strategy for Genomics at Genome. One, both in Sydney.

Pete Meyers

Mr. Pete A. Meyers serves as Non-Executive Director of Prima Biomed Ltd. Mr. Meyers is currently the Chief Financial Officer of Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX). From May 2016 to January 2017, Mr. Meyers served as the Chief Financial Officer of Motif BioSciences Inc. (NASDAQ: MTFB; AIM: MTFB), where he led the execution of the company’s November 2016 US IPO. From August 2013 to March 2016, Mr. Meyers served as Chief Financial Officer and Treasurer of TetraLogic Pharmaceuticals Corporation (NASDAQ: TLOG), where he led the execution of the company’s December 2013 IPO and subsequent acquisition of Shape Pharmaceuticals, Inc. Prior to his role at TetraLogic, Mr. Meyers spent 18 years in health care investment banking, holding positions of increasing responsibility at Dillon, Read & Co., Credit Suisse First Boston LLC and, most recently, as Co-Head of Global Health Care Investment Banking at Deutsche Bank Securities Inc. Mr. Meyers is the Chairman and President of The Thomas M. Brennan Memorial Foundation, Inc. He earned a Bachelor of Science degree in Finance from Boston College and a Master of Business Administration degree from Columbia Business School.

Matthew Gregorowski

Basic Compensation

Name Fiscal Year Total

Marc Voigt

668,157

Deanne Miller

366,450

Frederic Triebel

381,847

Grant Chamberlain

--

Russell Howard

90,000

Pete Meyers

189,810

Matthew Gregorowski

--
As Of  29 Jun 2017